Cargando…
Global guidance for the recognition, diagnosis, and management of tumor‐induced osteomalacia
Tumor‐induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by mesenchymal tumors that secrete fibroblast growth factor 23 (FGF23). Patients present with progressive bone pain, muscle weakness, and fragility fractures. TIO is characterized by hypophosphatemia, excess renal phosphate ex...
Autores principales: | Jan de Beur, Suzanne M., Minisola, Salvatore, Xia, Wei‐bo, Abrahamsen, Bo, Body, Jean‐Jacques, Brandi, Maria Luisa, Clifton‐Bligh, Roderick, Collins, Michael, Florenzano, Pablo, Houillier, Pascal, Imanishi, Yasuo, Imel, Erik A., Khan, Aliya A., Zillikens, M. Carola, Fukumoto, Seiji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108006/ https://www.ncbi.nlm.nih.gov/pubmed/36511653 http://dx.doi.org/10.1111/joim.13593 |
Ejemplares similares
-
Tumor-Induced Osteomalacia: A Systematic Clinical Review of 895 Cases
por: Bosman, Ariadne, et al.
Publicado: (2022) -
Epidemiology of Tumor-Induced Osteomalacia in Denmark
por: Abrahamsen, Bo, et al.
Publicado: (2021) -
Tumor-induced osteomalacia
por: Florenzano, Pablo, et al.
Publicado: (2017) -
Diagnostic Modalities for FGF23-Producing Tumors in Patients with Tumor-Induced Osteomalacia
por: Fukumoto, Seiji
Publicado: (2014) -
Burosumab for the Treatment of Tumor‐Induced Osteomalacia
por: Jan de Beur, Suzanne M, et al.
Publicado: (2021)